Literature DB >> 18515557

Susceptibility to nontuberculous mycobacterial lung disease.

P Sexton1, A C Harrison.   

Abstract

The nontuberculous mycobacteria (NTM) exhibit heterogeneous pathogenicity in humans. Articles on known and potential human factors capable of producing susceptibility to NTM lung disease (NTMLD) were identified by a systematic search of the medical literature, and are reviewed in the present study. Patients with pre-existing structural lung disease are known to be at risk of NTMLD. Other susceptible groups have become recognised since the 1980s, in particular middle-aged nonsmokers without previous lung disease (a group including those with Lady Windermere syndrome) and patients with genetically determined defects of cell-mediated immunity, including abnormalities of the interleukin-12/interferon-gamma axis, certain human leukocyte antigen alleles, cystic fibrosis transmembrane conductance regulator mutations, and polymorphisms of solute carrier 11A1 (or natural resistance-associated macrophage protein 1) and the vitamin D receptor. Information is also accruing about acquired systemic causes of susceptibility to NTMLD, including inhibitory antibodies directed against interferon-gamma, post-menopausal waning of endogenous oestrogen levels, coeliac disease and exposure to use of dietary phyto-oestrogens. It is not known whether immunosuppressive factors, such as oral corticosteroid treatment, chronic renal failure, diabetes mellitus and other known risk factors for pulmonary tuberculosis, are also risk factors for the development of NTMLD. Caution is appropriate in managing such patients.

Entities:  

Mesh:

Year:  2008        PMID: 18515557     DOI: 10.1183/09031936.00140007

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  39 in total

Review 1.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

2.  Multiple strains of non-tuberculous mycobacteria in a patient with cystic fibrosis.

Authors:  Sarah M N Brown
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

Review 3.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

4.  Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease.

Authors:  S-Y Kim; W-J Koh; H Y Park; K Jeon; O J Kwon; S-N Cho; S J Shin
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

5.  Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease.

Authors:  Meghan L O'Connell; Kate E Birkenkamp; David E Kleiner; Les R Folio; Steven M Holland; Kenneth N Olivier
Journal:  Chest       Date:  2011-12-22       Impact factor: 9.410

6.  Comparison of the incidence between tuberculosis and nontuberculous mycobacterial disease after gastrectomy.

Authors:  C H Kim; K H Im; S S Yoo; S Y Lee; S I Cha; H Y Jung; J Y Park; W Yu; J Lee
Journal:  Infection       Date:  2014-05-10       Impact factor: 3.553

7.  HLA antigens and nontuberculous mycobacterial lung disease in Korean patients.

Authors:  Sang-Won Um; Chang-Seok Ki; O Jung Kwon; Won-Jung Koh
Journal:  Lung       Date:  2009-02-14       Impact factor: 2.584

8.  Management of pulmonary nontuberculous mycobacterial disease.

Authors:  Kathleen L Horan; Shawn J Skerrett
Journal:  F1000 Med Rep       Date:  2009-12-15

Review 9.  Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.

Authors:  Pamela J McShane; Jeffrey Glassroth
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

10.  Cystic fibrosis and estrogens: a perfect storm.

Authors:  Pamela L Zeitlin
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.